Sandoz

Novartis sues FDA over its stance on Sanofi blockbuster’s exclusivity
Novartis sues FDA over its stance on Sanofi blockbuster’s exclusivity
Endpoints
Novartis
generics
Sandoz
FDA
Aubagio
multiple sclerosis
MS
Flag link:
GlaxoSmithKline to shut down antibiotics production, cut 300 jobs in wake of Novartis buyout
GlaxoSmithKline to shut down antibiotics production, cut 300 jobs in wake of Novartis buyout
Fierce Pharma
GSK
Novartis
Sandoz
layoffs
antibiotics
drug manufacturing
Flag link:
Novartis' Sandoz doubles down on antibiotics with $500M deal for GSK brands
Novartis' Sandoz doubles down on antibiotics with $500M deal for GSK brands
Fierce Pharma
Novartis
Sandoz
generics
antibiotics
Flag link:
Sandoz working to overcome barriers to greater biosimilars uptake in US
Sandoz working to overcome barriers to greater biosimilars uptake in US
Biopharma Reporter
Sandoz
biosimilars
Novartis
Flag link:
Sandoz earmarks $175M to upgrade tech at European hub for antibiotics manufacturing
Sandoz earmarks $175M to upgrade tech at European hub for antibiotics manufacturing
BioPharma Dive
Novartis
Sandoz
Europe
antibiotics
drug manufacturing
Flag link:
Novartis to provide 'no profit' COVID-19 drugs to low income countries
Novartis to provide 'no profit' COVID-19 drugs to low income countries
Reuters
Novartis
Sandoz
non-profits
developing countries
generics
Flag link:
Teva bails on price-fixing settlement in gamble on its role fighting COVID-19: report
Teva bails on price-fixing settlement in gamble on its role fighting COVID-19: report
Fierce Pharma
Teva Pharmaceutical
price fixing
generics
COVID-19
Sandoz
JNJ
Novartis
Taro Pharmaceuticals
Flag link:
Novartis cancels $1B sale of generics after antitrust concerns forced delays
Novartis cancels $1B sale of generics after antitrust concerns forced delays
Endpoints
Novartis
generics
Sandoz
antitrust
Flag link:
Sandoz Pays $195 Million to Settle Criminal Antitrust Charges in Sweeping Federal Probe
Sandoz Pays $195 Million to Settle Criminal Antitrust Charges in Sweeping Federal Probe
BioSpace
Sandoz
generics
Novartis
antitrust
Flag link:
Sandoz pledges 'stable' pricing for generics, antibiotics amid COVID-19 supply chain worries
Sandoz pledges 'stable' pricing for generics, antibiotics amid COVID-19 supply chain worries
Fierce Pharma
Sandoz
generics
antibiotics
COVID-19
coronaviruses
Flag link:
Former Novartis exec pleads guilty to generic price fixing
Former Novartis exec pleads guilty to generic price fixing
Endpoints
Novartis
Sandoz
price fixing
generics
DOJ
Flag link:
Sandoz Completes Acquisition of Aspen's Japanese Operations
Sandoz Completes Acquisition of Aspen's Japanese Operations
BioSpace
Sandoz
Aspen Global
Japan
M&A
Novartis
Flag link:
Novartis' Sandoz loses bid to break United Therapeutics' exclusive device deal for Remodulin
Novartis' Sandoz loses bid to break United Therapeutics' exclusive device deal for Remodulin
Fierce Pharma
Novartis
Sandoz
United Therapeutics
Remodulin
Flag link:
Novartis' Generics Unit to Buy Aspen's Japanese Operations
Novartis' Generics Unit to Buy Aspen's Japanese Operations
Yahoo/Zacks.com
Novartis
generics
Sandoz
M&A
Japan
Aspen Pharmacare
Aspen Global
Flag link:
Novartis takes a step back from marketing Pear prescription digital therapeutics
Novartis takes a step back from marketing Pear prescription digital therapeutics
Biopharma Dive
Novartis
Sandoz
Pear Therapeutics
digital therapeutics
opioid abuse
Flag link:
Why Bausch Health Companies Stock Sank Today
Why Bausch Health Companies Stock Sank Today
Motley Fool
Bausch Health
Novartis
Sandoz
Xifaxan
patents
Flag link:
Novartis strikes marketing deal for Polpharma’s potential Tysabri biosimilar
Novartis strikes marketing deal for Polpharma’s potential Tysabri biosimilar
Pharmaforum
Novartis
Sandoz
generics
biosimilars
Tysabri
Polpharma
Flag link:
Novartis’ Sandoz to appeal US district court ruling on biosimilar Erelzi
Novartis’ Sandoz to appeal US district court ruling on biosimilar Erelzi
Pharmaceutical Business Review
Novartis
Sandoz
biosimilars
Amgen
Enbrel
patents
Erelzi
Flag link:
Enbrel ruling lifts Amgen shares
Enbrel ruling lifts Amgen shares
BioCentury
Amgen
Enbrel
patents
Sandoz
generics
Flag link:
Sandoz recruits first patient in clinical study for proposed biosimilar denosumab in osteoporosis
Sandoz recruits first patient in clinical study for proposed biosimilar denosumab in osteoporosis
Pharmaceutical Business Review
Novartis
Sandoz
biosimilars
clinical trials
denosumab
osteoporosis
Prolia
Xgeva
Flag link:

Pages